# Phase 1 Study of DW-0919 & DW-0920 in Healthy Male Volunteers Under Fasting Condition

> **NCT01606059** · PHASE1 · COMPLETED · sponsor: **Daewon Pharmaceutical Co., Ltd.** · enrollment: 30 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** DW-0920
- **DRUG:** DW-0919

## Key facts

- **NCT ID:** NCT01606059
- **Lead sponsor:** Daewon Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-05
- **Primary completion:** 2012-06
- **Final completion:** 2012-06
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2016-10-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01606059

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01606059, "Phase 1 Study of DW-0919 & DW-0920 in Healthy Male Volunteers Under Fasting Condition". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT01606059. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*